{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:42:24Z","timestamp":1794062544149,"version":"4.8.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1038\/s41569-022-00705-w","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T13:04:08Z","timestamp":1652792648000},"page":"737-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["The need for increased pragmatism in cardiovascular clinical trials"],"prefix":"10.1038","volume":"19","author":[{"given":"Muhammad Shariq","family":"Usman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriette G. C.","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3222-1719","authenticated-orcid":false,"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-8093","authenticated-orcid":false,"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Spertus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4413-9736","authenticated-orcid":false,"given":"Stefan K.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"705_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcab058","author":"JW Zhu","year":"2021","unstructured":"Zhu, J. W. et al. Global representation of heart failure clinical trial leaders, collaborators, and enrolled participants: a bibliometric review 2000\u20132020. Eur. Heart J. Qual. Care Clin. Outcomes https:\/\/doi.org\/10.1093\/ehjqcco\/qcab058 (2021).","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"705_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/0021-9681(67)90041-0","volume":"20","author":"D Schwartz","year":"1967","unstructured":"Schwartz, D. & Lellouch, J. Explanatory and pragmatic attitudes in therapeutical trials. J. Chronic Dis. 20, 637\u2013648 (1967).","journal-title":"J. Chronic Dis."},{"key":"705_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/BSD.0000000000000588","volume":"30","author":"Z Merali","year":"2017","unstructured":"Merali, Z. & Wilson, J. R. Explanatory versus pragmatic trials: an essential concept in study design and interpretation. Clin. Spine Surg. 30, 404\u2013406 (2017).","journal-title":"Clin. Spine Surg."},{"key":"705_CR4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford, I. & Norrie, J. Pragmatic Trials. N. Engl. J. Med. 375, 454\u2013463 (2016).","journal-title":"N. Engl. J. Med."},{"key":"705_CR5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/ejhf.2248","volume":"23","author":"HGC Van Spall","year":"2021","unstructured":"Van Spall, H. G. C., Averbuch, T., Damman, K. & Voors, A. A. Risk and risk reduction in trials of heart failure with reduced ejection fraction: absolute or relative? Eur. J. Heart Fail. 23, 1437\u20131444 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"705_CR6","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.jacc.2016.09.936","volume":"68","author":"JP Ferreira","year":"2016","unstructured":"Ferreira, J. P. et al. Natriuretic peptides, 6-min walk test, and quality-of-life questionnaires as clinically meaningful endpoints in HF trials. J. Am. Coll. Cardiol. 68, 2690\u20132707 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"705_CR7","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/CIRCULATIONAHA.118.034668","volume":"138","author":"SJ Greene","year":"2018","unstructured":"Greene, S. J. et al. Reassessing the role of surrogate end points in drug development for heart failure. Circulation 138, 1039\u20131053 (2018).","journal-title":"Circulation"},{"key":"705_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jclinepi.2008.12.011","volume":"62","author":"KE Thorpe","year":"2009","unstructured":"Thorpe, K. E. et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J. Clin. Epidemiol. 62, 464\u2013475 (2009).","journal-title":"J. Clin. Epidemiol."},{"key":"705_CR9","doi-asserted-by":"publisher","first-page":"h2147","DOI":"10.1136\/bmj.h2147","volume":"350","author":"K Loudon","year":"2015","unstructured":"Loudon, K. et al. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 350, h2147 (2015).","journal-title":"BMJ"},{"key":"705_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00590-021-03137-3","author":"L Farrow","year":"2021","unstructured":"Farrow, L., Gardner, W. T., Ablett, A. D., Kutuzov, V. & Johnstone, A. A review of trauma and orthopaedic randomised clinical trials published in high-impact general medical journals. Eur. J. Orthop. Surg. Traumatol. https:\/\/doi.org\/10.1007\/s00590-021-03137-3 (2021).","journal-title":"Eur. J. Orthop. Surg. Traumatol."},{"key":"705_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/j.pain.0000000000002317","volume":"163","author":"D Hohenschurz-Schmidt","year":"2022","unstructured":"Hohenschurz-Schmidt, D. et al. Pragmatic trials of pain therapies: a systematic review of methods. Pain 163, 21\u201346 (2022).","journal-title":"Pain"},{"key":"705_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003529","volume":"10","author":"H Burnett","year":"2017","unstructured":"Burnett, H. et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction. Circ. Heart Fail. 10, e003529 (2017).","journal-title":"Circ. Heart Fail."},{"key":"705_CR13","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jamacardio.2020.0898","volume":"5","author":"NS Bassi","year":"2020","unstructured":"Bassi, N. S., Ziaeian, B., Yancy, C. W. & Fonarow, G. C. Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure. JAMA Cardiol. 5, 948\u2013951 (2020).","journal-title":"JAMA Cardiol."},{"key":"705_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJMoa043399","volume":"352","author":"GH Bardy","year":"2005","unstructured":"Bardy, G. H. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352, 225\u2013237 (2005).","journal-title":"N. Engl. J. Med."},{"key":"705_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa050496","volume":"352","author":"JG Cleland","year":"2005","unstructured":"Cleland, J. G. et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352, 1539\u20131549 (2005).","journal-title":"N. Engl. J. Med."},{"key":"705_CR16","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.ejheart.2005.08.005","volume":"7","author":"R Roccaforte","year":"2005","unstructured":"Roccaforte, R., Demers, C., Baldassarre, F., Teo, K. K. & Yusuf, S. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients: a meta-analysis. Eur. J. Heart Fail. 7, 1133\u20131144 (2005).","journal-title":"Eur. J. Heart Fail."},{"key":"705_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1136\/bmj.323.7315.715","volume":"323","author":"L Blue","year":"2001","unstructured":"Blue, L. et al. Randomised controlled trial of specialist nurse intervention in heart failure. BMJ 323, 715\u2013718 (2001).","journal-title":"BMJ"},{"key":"705_CR18","doi-asserted-by":"publisher","first-page":"l223","DOI":"10.1136\/bmj.l223","volume":"364","author":"CJ Taylor","year":"2019","unstructured":"Taylor, C. J. et al. Trends in survival after a diagnosis of heart failure in the United Kingdom 2000\u20132017: population based cohort study. BMJ 364, l223 (2019).","journal-title":"BMJ"},{"key":"705_CR19","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","volume":"175","author":"Y Gerber","year":"2015","unstructured":"Gerber, Y. et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern. Med. 175, 996\u20131004 (2015).","journal-title":"JAMA Intern. Med."},{"key":"705_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/fampra\/cmx040","volume":"34","author":"CJ Taylor","year":"2017","unstructured":"Taylor, C. J. et al. Survival following a diagnosis of heart failure in primary care. Fam. Pract. 34, 161\u2013168 (2017).","journal-title":"Fam. Pract."},{"key":"705_CR21","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1001\/jamacardio.2019.3593","volume":"4","author":"N Conrad","year":"2019","unstructured":"Conrad, N. et al. Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86000 individuals. JAMA Cardiol. 4, 1102\u20131111 (2019).","journal-title":"JAMA Cardiol."},{"key":"705_CR22","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ahj.2013.12.030","volume":"167","author":"S Coffey","year":"2014","unstructured":"Coffey, S., Cox, B. & Williams, M. J. Lack of progress in valvular heart disease in the pre-transcatheter aortic valve replacement era: increasing deaths and minimal change in mortality rate over the past three decades. Am. Heart J. 167, 562\u2013567.e2 (2014).","journal-title":"Am. Heart J."},{"key":"705_CR23","doi-asserted-by":"publisher","first-page":"m2724","DOI":"10.1136\/bmj.m2724","volume":"370","author":"N Vinter","year":"2020","unstructured":"Vinter, N. et al. Trends in excess mortality associated with atrial fibrillation over 45 years (Framingham Heart Study): community based cohort study. BMJ 370, m2724 (2020).","journal-title":"BMJ"},{"key":"705_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020163","volume":"10","author":"Y Tanaka","year":"2021","unstructured":"Tanaka, Y. et al. Trends in cardiovascular mortality related to atrial fibrillation in the United States, 2011 to 2018. J. Am. Heart Assoc. 10, e020163 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"705_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"J Greene Stephen","year":"2018","unstructured":"Greene Stephen, J. et al. Medical therapy for heart failure with reduced ejection fraction. J. Am. Coll. Cardiol. 72, 351\u2013366 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"705_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamacardio.2020.0640","volume":"5","author":"M Fiuzat","year":"2020","unstructured":"Fiuzat, M. et al. Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 5, 757\u2013764 (2020).","journal-title":"JAMA Cardiol."},{"key":"705_CR27","first-page":"41","volume":"24","author":"K Keramida","year":"2020","unstructured":"Keramida, K. & Filippatos, G. Heart failure guidelines implementation: lifting barriers using registries and networks. Anatol. J. Cardiol. 24, 41\u201342 (2020).","journal-title":"Anatol. J. Cardiol."},{"key":"705_CR28","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/ejhf.2331","volume":"23","author":"MS Usman","year":"2021","unstructured":"Usman, M. S., Pitt, B. & Butler, J. Target trial emulations: bridging the gap between clinical trial and real-world data. Eur. J. Heart Fail. 23, 1708\u20131711 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"705_CR29","doi-asserted-by":"publisher","first-page":"g7731","DOI":"10.1136\/bmj.g7731","volume":"349","author":"P Sedgwick","year":"2014","unstructured":"Sedgwick, P. Bias in observational study designs: prospective cohort studies. BMJ 349, g7731 (2014).","journal-title":"BMJ"},{"key":"705_CR30","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jacc.2020.05.069","volume":"76","author":"AC Fanaroff","year":"2020","unstructured":"Fanaroff, A. C. et al. Randomized trials versus common sense and clinical observation: JACC review topic of the week. J. Am. Coll. Cardiol. 76, 580\u2013589 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"705_CR31","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/eurheartj\/ehs348","volume":"34","author":"MG Whitbeck","year":"2013","unstructured":"Whitbeck, M. G. et al. Increased mortality among patients taking digoxin \u2014 analysis from the AFFIRM study. Eur. Heart J. 34, 1481\u20131488 (2013).","journal-title":"Eur. Heart J."},{"key":"705_CR32","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/eurheartj\/eht120","volume":"34","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade, M. et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur. Heart J. 34, 1489\u20131497 (2013).","journal-title":"Eur. Heart J."},{"key":"705_CR33","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","volume":"297","author":"HG Van Spall","year":"2007","unstructured":"Van Spall, H. G., Toren, A., Kiss, A. & Fowler, R. A. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297, 1233\u20131240 (2007).","journal-title":"JAMA"},{"key":"705_CR34","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1001\/jamainternmed.2020.2750","volume":"180","author":"MG Nanna","year":"2020","unstructured":"Nanna, M. G., Chen, S. T., Nelson, A. J., Navar, A. M. & Peterson, E. D. Representation of older adults in cardiovascular disease trials since the inclusion across the lifespan policy. JAMA Intern. Med. 180, 1531\u20131533 (2020).","journal-title":"JAMA Intern. Med."},{"key":"705_CR35","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1001\/jama.2011.1886","volume":"306","author":"AR Jadad","year":"2011","unstructured":"Jadad, A. R., To, M. J., Emara, M. & Jones, J. Consideration of multiple chronic diseases in randomized controlled trials. JAMA 306, 2670\u20132672 (2011).","journal-title":"JAMA"},{"key":"705_CR36","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1161\/CIR.0000000000000128","volume":"130","author":"DK Arnett","year":"2014","unstructured":"Arnett, D. K. et al. AHA\/ACC\/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions. Circulation 130, 1662\u20131667 (2014).","journal-title":"Circulation"},{"key":"705_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ejhf.2034","volume":"23","author":"S Whitelaw","year":"2021","unstructured":"Whitelaw, S. et al. Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review. Eur. J. Heart Fail. 23, 15\u201324 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"705_CR38","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","volume":"379","author":"J-F Obadia","year":"2018","unstructured":"Obadia, J.-F. et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N. Engl. J. Med. 379, 2297\u20132306 (2018).","journal-title":"N. Engl. J. Med."},{"key":"705_CR39","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone, G. W. et al. Transcatheter mitral-valve repair in patients with heart failure. N. Engl. J. Med. 379, 2307\u20132318 (2018).","journal-title":"N. Engl. J. Med."},{"key":"705_CR40","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray, J. J. V. et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993\u20131004 (2014).","journal-title":"N. Engl. J. Med."},{"key":"705_CR41","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jchf.2020.05.005","volume":"8","author":"DL Mann","year":"2020","unstructured":"Mann, D. L. et al. Sacubitril\/valsartan in advanced heart failure with reduced ejection fraction: rationale and design of the LIFE trial. JACC Heart Fail. 8, 789\u2013799 (2020).","journal-title":"JACC Heart Fail."},{"key":"705_CR42","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jchf.2018.04.014","volume":"6","author":"A Samman Tahhan","year":"2018","unstructured":"Samman Tahhan, A. et al. Design elements and enrollment patterns of contemporary trials in heart failure with preserved ejection fraction. JACC Heart Fail. 6, 714\u2013717 (2018).","journal-title":"JACC Heart Fail."},{"key":"705_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/CIRCRESAHA.113.302851","volume":"114","author":"L Moy\u00e9","year":"2014","unstructured":"Moy\u00e9, L. Clinical trials in cardiology. Circ. Res. 114, 28\u201331 (2014).","journal-title":"Circ. Res."},{"key":"705_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127242","volume":"10","author":"RJ Williams","year":"2015","unstructured":"Williams, R. J., Tse, T., DiPiazza, K. & Zarin, D. A. Terminated trials in the clinicaltrials.gov results database: evaluation of availability of primary outcome data and reasons for termination. PLoS ONE 10, e0127242 (2015).","journal-title":"PLoS ONE"},{"key":"705_CR45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008685","volume":"15","author":"S Wei","year":"2022","unstructured":"Wei, S. et al. Factors associated with racial and ethnic diversity among heart failure trial participants: a systematic bibliometric review. Circ. Heart Fail. 15, e008685 (2022).","journal-title":"Circ. Heart Fail."},{"key":"705_CR46","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015594","volume":"9","author":"MS Khan","year":"2020","unstructured":"Khan, M. S. et al. Ten\u2010year trends in enrollment of women and minorities in pivotal trials supporting recent us food and drug administration approval of novel cardiometabolic drugs. J. Am. Heart Assoc. 9, e015594 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"705_CR47","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jchf.2019.07.011","volume":"7","author":"SJ Greene","year":"2019","unstructured":"Greene, S. J. et al. Representativeness of a heart failure trial by race and sex: results from ASCEND-HF and GWTG-HF. JACC Heart Fail. 7, 980\u2013992 (2019).","journal-title":"JACC Heart Fail."},{"key":"705_CR48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41591-020-0754-2","volume":"26","author":"A Bernabe-Ortiz","year":"2020","unstructured":"Bernabe-Ortiz, A. et al. Effect of salt substitution on community-wide blood pressure and hypertension incidence. Nat. Med. 26, 374\u2013378 (2020).","journal-title":"Nat. Med."},{"key":"705_CR49","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jama.2017.10565","volume":"318","author":"GM Felker","year":"2017","unstructured":"Felker, G. M. et al. Effect of natriuretic peptide\u2013guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 318, 713\u2013720 (2017).","journal-title":"JAMA"},{"key":"705_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1527-5299.2005.04239.x","volume":"11","author":"L Beck-da-Silva","year":"2005","unstructured":"Beck-da-Silva, L., de Bold, A., Fraser, M., Williams, K. & Haddad, H. BNP-guided therapy not better than expert\u2019s clinical assessment for beta-blocker titration in patients with heart failure. Congest. Heart Fail. 11, 248\u2013253 (2005).","journal-title":"Congest. Heart Fail."},{"key":"705_CR51","doi-asserted-by":"publisher","first-page":"n450","DOI":"10.1136\/bmj.n450","volume":"372","author":"KA McCord","year":"2021","unstructured":"McCord, K. A. et al. Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: meta-research study. BMJ 372, n450 (2021).","journal-title":"BMJ"},{"key":"705_CR52","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nrd.2017.1","volume":"16","author":"A Breckenridge","year":"2017","unstructured":"Breckenridge, A. et al. Poor medication adherence in clinical trials: consequences and solutions. Nat. Rev. Drug Discov. 16, 149\u2013150 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"705_CR53","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/CLEP.S188752","volume":"11","author":"DRT Laursen","year":"2019","unstructured":"Laursen, D. R. T., Paludan-M\u00fcller, A. S. & Hr\u00f3bjartsson, A. Randomized clinical trials with run-in periods: frequency, characteristics and reporting. Clin. Epidemiol. 11, 169\u2013184 (2019).","journal-title":"Clin. Epidemiol."},{"key":"705_CR54","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/08037050310022405","volume":"12","author":"WJ Verberk","year":"2003","unstructured":"Verberk, W. J. et al. Home versus Office Blood Pressure Measurements: Reduction of Unnecessary Rreatment Study: rationale and study design of the HOMERUS trial. Blood Press. 12, 326\u2013333 (2003).","journal-title":"Blood Press."},{"key":"705_CR55","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/HYPERTENSIONAHA.111.171074","volume":"58","author":"HAW van Onzenoort","year":"2011","unstructured":"van Onzenoort, H. A. W. et al. Participation in a clinical trial enhances adherence and persistence to treatment. Hypertension 58, 573\u2013578 (2011).","journal-title":"Hypertension"},{"key":"705_CR56","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/ehjcvp\/pvy028","volume":"4","author":"A Vonbank","year":"2018","unstructured":"Vonbank, A. et al. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. Eur. Heart J. Cardiovasc. Pharmacother. 4, 230\u2013236 (2018).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"705_CR57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1472-6904-11-4","volume":"11","author":"J Lachaine","year":"2011","unstructured":"Lachaine, J., Beauchemin, C. & Ramos, E. Use, tolerability and compliance of spironolactone in the treatment of heart failure. BMC Clin. Pharmacol. 11, 4 (2011).","journal-title":"BMC Clin. Pharmacol."},{"key":"705_CR58","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jtcvs.2011.02.035","volume":"142","author":"TJ Gardner","year":"2011","unstructured":"Gardner, T. J., Miller, M. A., O\u2019Gara, P. T. & Gelijns, A. C. Building an infrastructure for clinical trials in cardiac surgery. J. Thorac. Cardiovasc. Surg. 142, 265\u2013266 (2011).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"705_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038863","volume":"10","author":"TJ Moore","year":"2020","unstructured":"Moore, T. J., Heyward, J., Anderson, G. & Alexander, G. C. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional study. BMJ Open 10, e038863 (2020).","journal-title":"BMJ Open"},{"key":"705_CR60","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ahj.2004.04.049","volume":"149","author":"EL Eisenstein","year":"2005","unstructured":"Eisenstein, E. L. et al. Reducing the costs of phase III cardiovascular clinical trials. Am. Heart J. 149, 482\u2013488 (2005).","journal-title":"Am. Heart J."},{"key":"705_CR61","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1056\/NEJMoa1308789","volume":"369","author":"O Fr\u00f6bert","year":"2013","unstructured":"Fr\u00f6bert, O. et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N. Engl. J. Med. 369, 1587\u20131597 (2013).","journal-title":"N. Engl. J. Med."},{"key":"705_CR62","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1056\/NEJMoa2105675","volume":"385","author":"B Neal","year":"2021","unstructured":"Neal, B. et al. Effect of salt substitution on cardiovascular events and death. N. Engl. J. Med. 385, 1067\u20131077 (2021).","journal-title":"N. Engl. J. Med."},{"key":"705_CR63","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005285","volume":"6","author":"B Bikdeli","year":"2017","unstructured":"Bikdeli, B. et al. Two decades of cardiovascular trials with primary surrogate endpoints: 1990\u20132011. J. Am. Heart Assoc. 6, e005285 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"705_CR64","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1161\/CIRCULATIONAHA.119.040798","volume":"140","author":"G Marquis-Gravel","year":"2019","unstructured":"Marquis-Gravel, G. et al. Technology-enabled clinical trials. Circulation 140, 1426\u20131436 (2019).","journal-title":"Circulation"},{"key":"705_CR65","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41746-020-0302-y","volume":"3","author":"OT Inan","year":"2020","unstructured":"Inan, O. T. et al. Digitizing clinical trials. NPJ Digit. Med. 3, 101 (2020).","journal-title":"NPJ Digit. Med."},{"key":"705_CR66","doi-asserted-by":"publisher","first-page":"212","DOI":"10.14797\/mdcj-16-3-212","volume":"16","author":"M Mori","year":"2020","unstructured":"Mori, M. et al. The promise of big data and digital solutions in building a cardiovascular learning system: opportunities and barriers. Methodist Debakey Cardiovasc. J. 16, 212\u2013219 (2020).","journal-title":"Methodist Debakey Cardiovasc. J."},{"key":"705_CR67","doi-asserted-by":"publisher","first-page":"m3721","DOI":"10.1136\/bmj.m3721","volume":"372","author":"L Wolfenden","year":"2021","unstructured":"Wolfenden, L. et al. Designing and undertaking randomised implementation trials: guide for researchers. BMJ 372, m3721 (2021).","journal-title":"BMJ"},{"key":"705_CR68","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/MLR.0b013e3182408812","volume":"50","author":"GM Curran","year":"2012","unstructured":"Curran, G. M., Bauer, M., Mittman, B., Pyne, J. M. & Stetler, C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med. Care 50, 217\u2013226 (2012).","journal-title":"Med. Care"},{"key":"705_CR69","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1111\/jgs.16622","volume":"68","author":"LN Gitlin","year":"2020","unstructured":"Gitlin, L. N. et al. Dissemination and implementation of evidence-based dementia care using embedded pragmatic trials. J. Am. Geriatr. Soc. 68, S28\u2013S36 (2020).","journal-title":"J. Am. Geriatr. Soc."},{"key":"705_CR70","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1198\/016214501753168154","volume":"96","author":"MA Hern\u00e1n","year":"2001","unstructured":"Hern\u00e1n, M. A., Brumback, B. & Robins, J. M. Marginal structural models to estimate the joint causal effect of nonrandomized treatments. J. Am. Stat. Assoc. 96, 440\u2013448 (2001).","journal-title":"J. Am. Stat. Assoc."},{"key":"705_CR71","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/sim.1219","volume":"21","author":"M Branson","year":"2002","unstructured":"Branson, M. & Whitehead, J. Estimating a treatment effect in survival studies in which patients switch treatment. Stat. Med. 21, 2449\u20132463 (2002).","journal-title":"Stat. Med."},{"key":"705_CR72","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1177\/0962280216642264","volume":"27","author":"NR Latimer","year":"2018","unstructured":"Latimer, N. R., Abrams, K. R., Lambert, P. C., Morden, J. P. & Crowther, M. J. Assessing methods for dealing with treatment switching in clinical trials: a follow-up simulation study. Stat. Methods Med. Res. 27, 765\u2013784 (2018).","journal-title":"Stat. Methods Med. Res."},{"key":"705_CR73","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0197-2456(93)90012-3","volume":"14","author":"SD Mark","year":"1993","unstructured":"Mark, S. D. & Robins, J. M. A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial. Control. Clin. Trials 14, 79\u201397 (1993).","journal-title":"Control. Clin. Trials"},{"key":"705_CR74","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1177\/1740774516646578","volume":"13","author":"AJ Cook","year":"2016","unstructured":"Cook, A. J., Delong, E., Murray, D. M., Vollmer, W. M. & Heagerty, P. J. Statistical lessons learned for designing cluster randomized pragmatic clinical trials from the NIH Health Care Systems Collaboratory Biostatistics and Design Core. Clin. Trials 13, 504\u2013512 (2016).","journal-title":"Clin. Trials"},{"key":"705_CR75","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamacardio.2019.3604","volume":"4","author":"N Sepehrvand","year":"2019","unstructured":"Sepehrvand, N. et al. Trends in the explanatory or pragmatic nature of cardiovascular clinical trials over 2 decades. JAMA Cardiol. 4, 1122\u20131128 (2019).","journal-title":"JAMA Cardiol."},{"key":"705_CR76","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jama.2019.0710","volume":"321","author":"HGC Van Spall","year":"2019","unstructured":"Van Spall, H. G. C. et al. Effect of patient-centered transitional care services on clinical outcomes in patients hospitalized for heart failure: the PACT-HF randomized clinical trial. JAMA 321, 753\u2013761 (2019).","journal-title":"JAMA"},{"key":"705_CR77","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ahj.2017.12.013","volume":"199","author":"HGC Van Spall","year":"2018","unstructured":"Van Spall, H. G. C. et al. Knowledge to action: rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial. Am. Heart J. 199, 75\u201382 (2018).","journal-title":"Am. Heart J."},{"key":"705_CR78","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/ejhf.765","volume":"19","author":"HGC Van Spall","year":"2017","unstructured":"Van Spall, H. G. C. et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur. J. Heart Fail. 19, 1427\u20131443 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"705_CR79","doi-asserted-by":"publisher","first-page":"774","DOI":"10.7326\/M14-0083","volume":"160","author":"C Feltner","year":"2014","unstructured":"Feltner, C. et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis. Ann. Intern. Med. 160, 774\u2013784 (2014).","journal-title":"Ann. Intern. Med."},{"key":"705_CR80","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007767","volume":"14","author":"JA Spertus","year":"2021","unstructured":"Spertus, J. A. et al. Novel trial design: CHIEF-HF. Circ. Heart Fail. 14, e007767 (2021).","journal-title":"Circ. Heart Fail."},{"key":"705_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01703-8","author":"JA Spertus","year":"2022","unstructured":"Spertus, J. A. et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat. Med.  28, 809\u2013813 (2022).","journal-title":"Nat. Med."},{"key":"705_CR82","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04564742 (2022)."},{"key":"705_CR83","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/cpt.1142","volume":"105","author":"MF Dockendorf","year":"2019","unstructured":"Dockendorf, M. F. et al. Leveraging digital health technologies and outpatient sampling in clinical drug development: a phase I exploratory study. Clin. Pharmacol. Ther. 105, 168\u2013176 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"705_CR84","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/CIRCULATIONAHA.115.019902","volume":"133","author":"RJ Mentz","year":"2016","unstructured":"Mentz, R. J. et al. Good clinical practice guidance and pragmatic clinical trials: balancing the best of both worlds. Circulation 133, 872\u2013880 (2016).","journal-title":"Circulation"},{"key":"705_CR85","unstructured":"World Health Organization. Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products http:\/\/www.femh-irb.org\/content_pages\/files_add\/doc_arb\/I01_9712011000.pdf (1995)."},{"key":"705_CR86","unstructured":"International Council for Harmonisation. ICH-E6 Good Clinical Practice (GCP), Explanatory Note https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6-R3_GCP-Principles_Draft_2021_0419.pdf (2021)."},{"key":"705_CR87","doi-asserted-by":"publisher","first-page":"103090","DOI":"10.1016\/j.jbi.2018.12.004","volume":"90","author":"B Claerhout","year":"2019","unstructured":"Claerhout, B. et al. Federated electronic health records research technology to support clinical trial protocol optimization: evidence from EHR4CR and the InSite platform. J. Biomed. Inf. 90, 103090 (2019).","journal-title":"J. Biomed. Inf."},{"key":"705_CR88","doi-asserted-by":"publisher","first-page":"635","DOI":"10.7326\/M15-1460","volume":"163","author":"AF Hernandez","year":"2015","unstructured":"Hernandez, A. F., Fleurence, R. L. & Rothman, R. L. The ADAPTABLE trial and PCORnet: shining light on a new research paradigm. Ann. Intern. Med. 163, 635\u2013636 (2015).","journal-title":"Ann. Intern. Med."},{"key":"705_CR89","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/cpt.946","volume":"103","author":"RA Miksad","year":"2018","unstructured":"Miksad, R. A. & Abernethy, A. P. Harnessing the power of real-world evidence (RWE): a checklist to ensure regulatory-grade data quality. Clin. Pharmacol. Ther. 103, 202\u2013205 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"705_CR90","doi-asserted-by":"publisher","first-page":"n857","DOI":"10.1136\/bmj.n857","volume":"373","author":"L Kwakkenbos","year":"2021","unstructured":"Kwakkenbos, L. et al. CONSORT extension for the reporting of randomised controlled trials conducted using cohorts and routinely collected data (CONSORT-ROUTINE): checklist with explanation and elaboration. BMJ 373, n857 (2021).","journal-title":"BMJ"},{"key":"705_CR91","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04727073 (2021)."},{"key":"705_CR92","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02901184 (2021)."},{"key":"705_CR93","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","volume":"384","author":"WS Jones","year":"2021","unstructured":"Jones, W. S. et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N. Engl. J. Med. 384, 1981\u20131990 (2021).","journal-title":"N. Engl. J. Med."},{"key":"705_CR94","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"ASCEND Study Collaborative Group","year":"2018","unstructured":"ASCEND Study Collaborative Groupet al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N. Engl. J. Med. 379, 1529\u20131539 (2018).","journal-title":"N. Engl. J. Med."},{"key":"705_CR95","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1056\/NEJMsa1107913","volume":"365","author":"NK Choudhry","year":"2011","unstructured":"Choudhry, N. K. et al. Full coverage for preventive medications after myocardial infarction. N. Engl. J. Med. 365, 2088\u20132097 (2011).","journal-title":"N. Engl. J. Med."},{"key":"705_CR96","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05130268 (2022)."},{"key":"705_CR97","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jchf.2021.01.013","volume":"9","author":"SJ Greene","year":"2021","unstructured":"Greene, S. J. et al. Pragmatic design of randomized clinical trials for heart failure: rationale and design of the TRANSFORM-HF Trial. JACC Heart Fail. 9, 325\u2013335 (2021).","journal-title":"JACC Heart Fail."},{"key":"705_CR98","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ahj.2021.01.018","volume":"235","author":"AP Ambrosy","year":"2021","unstructured":"Ambrosy, A. P. et al. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). Am. Heart J. 235, 54\u201364 (2021).","journal-title":"Am. Heart J."},{"key":"705_CR99","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04564742 (2022)."},{"key":"705_CR100","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04509674 (2022)."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-022-00705-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-022-00705-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-022-00705-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:18:52Z","timestamp":1733959132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-022-00705-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":100,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1038\/s41569-022-00705-w","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"11 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.G.C.V. is funded by the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. S.J.G. has received research support from the Duke University Department of Medicine Chair\u2019s Research Award, American Heart Association, Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, Pfizer and Sanofi; has served on advisory boards for Amgen, AstraZeneca, Bristol Myers Squibb, Cytokinetics, Roche Diagnostics and Sanofi; and serves as a consultant for Amgen, Bayer, Bristol Myers Squibb, Merck, PharmaIN, Roche Diagnostics, Sanofi, Tricog Health, Urovant Pharmaceuticals and Vifor. D.K.M. reports honoraria for clinical trial leadership from AbbVie, Akebia, Arena, AstraZeneca, Boehringer Ingelheim, CSL Behring, Dynavax, Eidos, Esperion, Lexicon, Lilly USA, Merck & Co, Novo Nordisk, Otsuka, Pfizer and Sanofi, and honoraria for consultancy from Afimmune, Applied Therapeutics, Bayer, Boehringer Ingelheim, CSL Behring, Lilly USA, Merck & Co, Metavant, Novo Nordisk and Sanofi. Z.A.A. reports institutional research grants to Columbia University from Abbott and Cardiovascular Systems; and is a consultant for Abbott, Abiomed, AstraZeneca and Shockwave. R.J.M. reports receiving personal fees from Amgen, Bayer, Boehringer Ingelheim, Merck & Co and Novartis International; and receiving research support and honoraria from Abbott Laboratories, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim\/Eli Lilly & Co, Boston Scientific Corporation, Cytokinetics, FAST BioMedical, Gilead Sciences, Innolife, Medtronic, Merck & Co, Novartis International, Relypsa, Respicardia, Windtree Therapeutics and ZOLL Medical Corporation. G.C.F. reports research support from the National Institutes of Health and consulting for Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Janssen, Medtronic, Merck and Novartis. J.A.S. is a consultant for Bayer, Janssen, Merck, Myokardia, Novartis, Terumo and United Healthcare; receives grant support from Janssen and Myokadia; and holds the copyright to the Peripheral Artery Questionnaire, Kansas City Cardiomyopathy Questionnaires and the Seattle Angina Questionnaire; and serves on the Board of Blue Cross\/Blue Shield of Kansas City. S.D.A. declares grants or personal fees from Abbott Vascular, Actimed, Amgen, AstraZeneca, Bayer, Bioventrix, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cordio, Janssen, Occlutech, Respicardia, Servier, Vifor Int. and V-Wave. J.B. has served as a consultant for Abbott, Adrenomed, Arena Pharma, Amgen, Applied Therapeutics, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Cardior, CVRx, Eli Lilly, G3 Pharma, Imbria, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Sequana Medical, V-Wave Limited and Vifor. S.K.J. has received institutional research\/grant support from AstraZeneca, Bayer, Janssen and Novartis. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}